Compound Detail
CHEMBL1431
METFORMIN 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1431 |
| Name | METFORMIN |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | XZWYZXLIPXDOLR-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
4
Targets
595
Activities
3
Assay Types
30
PK Parameters
20
Publications
5
Known Names
20
Indications
Molecular Properties
129.2
MW (Da)
-1.03
ALogP
2
HBA
4
HBD
89.0
PSA (Ų)
0.25
QED
0
Ro5 Violations
0
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1995 |
| Availability | Prescription |
| Chirality | Achiral |
Indications
Diabetes Mellitus Acute Coronary Syndrome Aging Atherosclerosis Bipolar Disorder Brain Neoplasms Brain Neoplasms Cognitive Dysfunction Cognitive Dysfunction Colorectal Neoplasms Colorectal Neoplasms Colorectal Neoplasms Colorectal Neoplasms Coronary Disease Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes, Gestational Endometrial Neoplasms Epilepsy Fatty Liver
ATC Classification
A10BA02
metformin
Level 1: ALIMENTARY TRACT AND METABOLISM
Level 2: DRUGS USED IN DIABETES
Activity Summary
IC50 592 meas. best 8.0
EC50 2 meas. best 6.57
Ki 1 meas.
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| MCF7 CHEMBL387 | IC50 | 8.0 | 8.0 | 9.9 | 1 |
| PC-3 CHEMBL390 | IC50 | 6.72 | 6.72 | 189.0 | 1 |
| HepG2 CHEMBL395 | EC50 | 6.57 | 6.57 | 270.0 | 1 |
| Dipeptidyl peptidase 4 CHEMBL284 | IC50 | 4.54 | 4.54 | 29000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 2833.33 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 4816.67 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 5257219.0 | ng.hr.mL-1 | Mus musculus |
| AUC | 292.9 | - | Chlorocebus sabaeus |
| AUC | 6230.08 | ng.hr.mL-1 | Mus musculus |
| AUC | 78670.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 2056.0 | mM.min | Mus musculus |
| AUC | 2477.0 | mM.min | Mus musculus |
| CL | 52.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 7.4 | mL.min-1.kg-1 | Homo sapiens |
| CL | 7.4 | mL.min-1.kg-1 | Homo sapiens |
| CL | - | mL.min-1.kg-1 | Homo sapiens |
| CL | 7.4 | mL.min-1.kg-1 | Homo sapiens |
| Cmax | 161802.28 | nM | Rattus norvegicus |
| Cmax | 13160.95 | nM | Rattus norvegicus |
| Cmax | 139660.91 | nM | Rattus norvegicus |
| Cmax | 741.0 | nM | Homo sapiens |
| Cmax | 741.0 | nM | Homo sapiens |
| Cmax | 15483.47 | nM | Mus musculus |
| F | 43.0 | % | Rattus norvegicus |
| F | 50.0 | % | Mus musculus |
| F | 50.0 | % | Mus musculus |
| Fu | 1.0 | - | Homo sapiens |
| Fu | 1.0 | - | Homo sapiens |
| Fu | 0.95 | - | Rattus norvegicus |
| MRT | 1.4 | hr | Homo sapiens |
| T1/2 | 1.7 | hr | Homo sapiens |
| T1/2 | 3.236 | hr | Rattus norvegicus |
| T1/2 | 6.0 | hr | Mus musculus |
| Tmax | 0.01667 | hr | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| MCF7 | IC50 | = | 9.9 | nM | 8.0 | Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth meas... | 33479633 |
| PC-3 | IC50 | = | 189.0 | nM | 6.72 | Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth meas... | 33479633 |
| HepG2 | EC50 | = | 270.0 | nM | 6.57 | Increase in glucose consumption in insulin-resistant human HepG2 cells after 24 ... | 21856048 |
| Dipeptidyl peptidase 4 | IC50 | = | 29000.0 | nM | 4.54 | Inhibition of DPP4 | 18068977 |
Literature References
Data from ChEMBL 36 via Core Engine